2017 01-15
Authors: Unger K, Fleischmann DF, Ruf V, Felsberg J, Piehlmaier D, Samaga D, Julia Hess J, Suresh MP, Mittelbronn M, Lauber K, Budach W, Sabel M, Rödel C, Reifenberger G, Herms J, Tonn JC, Zitzelsberger, Belka C, Niyazi M
The potential benefit of risk stratification using a 4-miRNA signature in combination with MGMT promoter methylation in IDH1/2 wild-type glioblastoma patients was assessed.
Neuro-Oncology Advances